Telix Pharmaceuticals Limited (TLX)
NASDAQ: TLX · Real-Time Price · USD
6.87
-0.10 (-1.43%)
At close: Mar 4, 2026, 4:00 PM EST
6.87
0.00 (0.00%)
After-hours: Mar 4, 2026, 5:38 PM EST

Telix Pharmaceuticals Cash Flow Statement

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
FY 2025FY 2024FY 2023FY 2021FY 2020
Period Ending
Dec '25 Dec '24 Dec '23 Dec '21 Dec '20
Net Income
-5.2737.922.59--
Depreciation & Amortization
21.415.284.16--
Stock-Based Compensation
19.3512.935.85--
Other Adjustments
-7.5714.3826.19--
Change in Receivables
-20.47-37.49-18.62--
Changes in Inventories
-7.64-2.13-6.55--
Changes in Accounts Payable
28.9828.8421.06--
Changes in Accrued Expenses
4.815.214.21--
Changes in Unearned Revenue
-9.13-6.23-3.43--
Changes in Other Operating Activities
-59.07-3.72-6.9-43.121.51
Operating Cash Flow
-17.2927.4914.27-43.121.51
Operating Cash Flow Growth
-92.60%---
Capital Expenditures
-25.69-9.12-6.31-0.97-0.19
Purchases of Intangible Assets
-18.08-13.07-0.8--0.06
Purchases of Investments
-0.89-32.91-8.7--
Payments for Business Acquisitions
-221.36-20.66---0.25
Other Investing Activities
-19.89-10.93-1.03-1.01-0.34
Investing Cash Flow
-285.92-86.69-16.84-1.98-0.84
Long-Term Debt Issued
0.53427.94.19--
Long-Term Debt Repaid
0.820.75-0.250.31
Net Long-Term Debt Issued (Repaid)
1.35428.654.190.250.31
Issuance of Common Stock
1.810.664.172.7527.07
Net Common Stock Issued (Repurchased)
1.810.664.172.7527.07
Other Financing Activities
-5.24-11.03-1.27-0.43-0.49
Financing Cash Flow
-3.72416.797.092.0726.27
Effect of Exchange Rate Changes on Cash and Cash Equivalents
8.8-1.890.99--
Net Cash Flow
-298.13355.75.52-43.0426.94
Free Cash Flow
-42.9918.377.97-44.11.32
Free Cash Flow Growth
-130.64%---
FCF Margin
-5.35%3.56%2.39%-798.67%32.84%
Free Cash Flow Per Share
-0.130.050.02-0.160.01
Levered Free Cash Flow
-52.1480.4714.62-102.37-32.94
Unlevered Free Cash Flow
-6.0467.1624.09-98.76-27.83
Updated Dec 31, 2025. Data Source: Fiscal.ai. Standard template. Financial Sources.
SEC Filings: 10-K · 10-Q